The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here, ...
Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...
XytriX™ Becomes First CTE Biotherapeutic to Reach FDA Under the Blast Overpressure Safety Act We have known about this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results